THOMSON REUTERS
CORTELLIS™

Portola Pharmaceuticals Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 18-Feb-2014

THOMSON REUTERS
3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

Return to Table of Contents

THOMSON REUTERS

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurateand validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

Return to Table of Contents

GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Return to Table of Contents

TABLE OF CONTENTS

Return to Table of Contents

Portola Pharmaceuticals Inc

COMPANY OVERVIEW

Company Name	Portola Pharmaceuticals Inc
Parent Company Name	Portola Pharmaceuticals Inc
Website	http://www.portola.com/
Country	US
Number of Drugs in Active Development	9
Number of Inactive Drugs	2
Number of Patents as Owner	51
Number of Patents as Third Party	0
Number of Deals	13
Key Indications	Rheumatoid arthritis,Inflammatory disease,Non-Hodgkin lymphoma,Cardiovascular disease,Coronary artery disease,Cancer,Chronic lymphocytic leukemia,Bleeding,Thrombosis,Allergy
Key Target-based Actions	Syk tyrosine kinase inhibitor,P2Y12 purinoceptor antagonist,Factor Xa antagonist,JAK tyrosine kinase inhibitor,Jak3 tyrosine kinase inhibitor,Jak1 tyrosine kinase inhibitor,Jak2 tyrosine kinase inhibitor,Factor Xa agonist,DNA polymerase alpha inhibitor,DNA primase inhibitor,Factor VIIa agonist,Factor X agonist,Ribonucleotide reductase inhibitor
Key Technologies	Small molecule therapeutic,Oral formulation,Intravenous formulation,Protein recombinant,Biological therapeutic,Infusion,Parenteral formulation unspecified,Stereochemistry,Drug combination,Peptide,Polynucleotide

COMPANY PROFILE

SUMMARY

Portola Pharmaceuticals Inc was spun-out from Millennium Pharmaceuticals in 2003 with cardiovascular technology formerly owned by COR Therapeutics, which was acquired by, and merged into, Millennium in February 2002. Portola is a privately-held biopharmaceutical company focused on the discovery and development of therapeutics for the treatment and prevention of severe cardiovascular diseases, especially thrombosis. Its R&D is particularly focused on well validated targets in odder to reduce safety and efficacy risks. Portola is currently interested to inlicense cardiology or inflammation treatments.

COMPANY LOCATION

Portola is located in South San Francisco, CA.

LICENSING AGREEMENTS

In June 2005, Portola and Astellas entered a license agreement to develop a selection Astellas's preclinical cardiovascular compounds.

FINANCIAL

In October 2013, Portola began an underwritten public offering of its common stock shares and was to raise approximately $100 million from the offering. Also, the offering would include shares from certain existing shareholders. Later that month, the company raised $100 million by the closing of the offering.

In October 2013, a lock-up restriction of 95,962 shares of the company's common stock was released.

In April 2013, Portola was planning an IPO of its stock. In May 2013, Portola priced the offering of 8,422,758 shares of its common stock at a price of $14.50 each. The underwriters were granted a 30-day over-allotment option to purchase up to an additional 1,263,413 shares at the offering price. The shares were expected to begin trading on the NASDAQ Global Market on May 22, 2013 under the trading symbol 'PTLA' and the offering was expected to close on May 28, 2013. Later that month, the offering was closed and raised net proceeds of $126 million. In December 2013, NASDAQ

Return to Table of Contents

reported that, Portola would be added to the NASDAQ Biotechnology Index, as a result of the annual re-ranking under the trading symbol 'PTLA', which would become effective prior to market open on December 23, 2013.

In November 2011, the company raised $89 million in a preferred stock financing.

In July 2008, the company raised $60 million in a preferred stock financing.

In May 2007, Portola raised $70 million in a series C preferred stock financing.

In October 2006, Portola secured $20 million in debt financing from Hercules Technology Growth Capital. The company planned to use the funds to advance development of its pipeline candidates.

In November 2005, Portola raised $46 million in a series B financing.

In December 2003, Portola raised $21 million in its series A financing round. The company intended to use the funding to support its R&D program in vascular thrombosis and inflammation underlying atherosclerosis.

Return to Table of Contents

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



Return to Table of Contents

Drugs by Indication Table

Indication	Active	Inactive	Total
Cardiovascular disease	5	3	8
Hematological disease	4	0	4
Neoplasm	4	0	4
Inflammatory disease	3	0	3
Musculoskeletal disease	2	0	2
Immune disorder	2	0	2
Neurological disease	0	1	1
Metabolic disorder	1	0	1
Dermatological disease	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Return to Table of Contents

Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Phase 2 Clinical	3
Discovery	2
Suspended	3
No Development Reported	2

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Screening/Evaluation	0	0	2	0	2
Drug - Early Research/Development	1	0	0	0	1
Drug - Development/Commercialization License	3	0	2	0	6
Drug - Development Services	3	0	1	0	4

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Cardiovascular disease	1	11
Hematological disease	1	10
Immune disorder	0	2
Neoplasm	0	2
Genitourinary disease	0	1
Neurological disease	0	1

Trials by Phase

Phase	Ongoing	All
Phase 3	1	2
Phase 2	0	6
Phase 1	0	12
Phase not specified	1	2

Return to Table of Contents

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	49	0	49
Endocrine disease	8	0	8
Gastrointestinal disease	10	0	10
Growth disorder	1	0	1
Hematological disease	42	0	42
Degeneration	2	0	2
Immune disorder	15	0	15
Psychiatric disorder	2	0	2
Musculoskeletal disease	12	0	12
Neoplasm	13	0	13
Ocular disease	6	0	6
Genetic disorder	8	0	8
Metabolic disorder	11	0	11
Mouth disease	6	0	6
Neurological disease	27	0	27
Respiratory disease	4	0	4
Inflammatory disease	15	0	15
Otorhinolaryngological disease	1	0	1
Gynecology and obstetrics	2	0	2
Dermatological disease	7	0	7

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Return to Table of Contents

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

betrixaban

betrixaban SNAPSHOT

Drug Name	betrixaban
Key Synonyms	betrixaban
Originator Company	Takeda Pharmaceutical Co Ltd
Active Companies	Lee's Pharmaceutical Holdings (Hong Kong) Ltd;Portola Pharmaceuticals Inc
Inactive Companies	Merck & Co Inc;Millennium Pharmaceuticals Inc
Highest Status	Phase 3 Clinical
Active Indications	Phlebothrombosis;Thromboembolism
Target-based Actions	Factor Xa antagonist
Other Actions	Coagulation inhibitor;Neuroprotectant
Technologies	Oral formulation;Small molecule therapeutic;Oral sustained release formulation
Last Change Date	01-Feb-2014

betrixaban DEVELOPMENT PROFILE

SUMMARY

Portola Pharmaceuticals, under license from Millennium Pharmaceuticals, is developing betrixaban (PRT-54021; PRT-021; structure shown), the lead from a series of small-molecule oral Factor Xa (FXa) inhibitors, as a long-acting formulation for the potential prevention and treatment of venous thrombosis and thromboembolic disorders.

In March 2012, the company began enrollment in a pivotal phase III study for hospital and post-discharge prevention of venous thromboembolism (VTE) in acute medically ill patients in the US.

The drug was previously developed for the prevention of stroke. In October 2008, Portola initiated a phase II trial for the prevention of stroke. In July 2009, Merck & Co, under license from Portola, took over development of betrixaban (as MK-4448) for the prevention of stroke in patients with atrial fibrillation. However, in March 2011, Merck decided to return all rights for betrixaban to Portola, following a review of its investigational portfolio and prioritization of its late-stage pipeline. Portola has reported no development since that time.

betrixaban DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date

Return to Table of Contents

Company	Indication	Country	Development Status	Date
Lee's Pharmaceutical Holdings (Hong Kong) Ltd	Phlebothrombosis	China	Phase 3 Clinical	29-Jan-2013
Portola Pharmaceuticals Inc	Phlebothrombosis	China	Phase 3 Clinical	29-Jan-2013
Portola Pharmaceuticals Inc	Phlebothrombosis	US	Phase 3 Clinical	30-Mar-2012
Portola Pharmaceuticals Inc	Thromboembolism	Canada	Phase 2 Clinical	31-May-2006
Portola Pharmaceuticals Inc	Thromboembolism	UK	Phase 1 Clinical	07-Feb-2005
Merck & Co Inc	Stroke	US	Discontinued	24-Mar-2011
Millennium Pharmaceuticals Inc	Thromboembolism	US	Discontinued	05-Aug-2004
Portola Pharmaceuticals Inc	Stroke	US	No Development Reported	24-Sep-2012

betrixaban CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
330942-05-7	1



Name	Type
betrixaban	INN; USAN
PRT-054021	Research Code
PRT-54021	Research Code
PRT-021	Research Code

Return to Table of Contents

CAS Registry Number:	Confidence Level:
353228-03-2	3



CAS Registry Number:	Confidence Level:
	3



CAS Registry Number:	Confidence Level:
	3



Return to Table of Contents

CAS Registry Number:	Confidence Level:
	3



betrixaban DRUG NAMES

Names	Type
PRT-054021	Research Code
Factor Xa inhibitors (oral/sustained release, embolism/thrombosis), Portola	
MK-4448	Research Code
betrixaban	INN, USAN
PRT-021	Research Code
Factor Xa inhibitors (embolism/thrombosis), Millennium	
PRT-54021	Research Code

Return to Table of Contents

betrixaban SALES AND FORECASTS

CHARTS







Return to Table of Contents

COMMENTARY

CONSENSUS SALES INFORMATION
Consensus forecast data for Portola are presented.

REGIONAL DEVELOPMENT AND MARKETING RIGHTS
In August 2004, Portola obtained exclusive rights to develop, market and commercialize Millennium's (subsidary of Takeda) Factor Xa inhibitors worldwide [552914].

In July 2009, Merck & Co signed an agreement with Portola to develop and commercialize betrixaban for the prevention of stroke in patients with atrial fibrillation worldwide [1024477]. By March 2010, the deal had closed [1082208]. In March 2011, Merck decided to return all rights for betrixaban to Portola [1179024].

In January 2013, Portola and Lee's Pharmaceutical entered into an agreement to collaborate on betrixaban development in China. Under the agreement terms, Lee's Pharmaceutical would support the clinical expansion of the phase III APEX study and would lead regulatory interactions with the Chinese SFDA; Lee's also retained an option to negotiate the commercialization rights to betrixaban in China for an exclusive period following the completion of the study [1364038].

betrixaban CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Thromboembolism											
0	0	1	1	0	1	0	0	1	1	2	3
Atrial flutter											
0	0	0	0	0	1	0	0	0	0	0	1
Atrial fibrillation											
0	0	0	0	0	1	0	0	0	0	0	1
Embolism and thrombosis											
0	0	0	0	0	0	0	1	0	0	0	1
Stroke											
0	0	0	0	0	0	0	1	0	0	0	1

Return to Table of Contents

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	1	2	0	3	0	3	1	1	2	9

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

betrixaban DEALS AND PATENTS

DEALS

Deals by Parent Company Chart





Return to Table of Contents

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Portola Pharmaceuticals Inc	1	1	1	0	3
Lee's Pharmaceutical Holdings (Hong Kong) Ltd	0	0	1	0	1
Merck & Co Inc	0	0	0	1	1
Takeda Pharmaceutical Co Ltd	1	0	0	0	1

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	2	1	3

Return to Table of Contents

PATENTS

Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Portola Pharmaceuticals Inc	9	0	9
Takeda Pharmaceutical Co Ltd	6	0	6
Merck & Co Inc	2	1	3
Individual	2	0	2
Pfizer Inc	1	0	1
Sigma-Aldrich Corp	0	1	1
Eastman Kodak Co	1	0	1

Return to Table of Contents

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	3
Component of Combination	3
Process	2
Formulation	2
New use	2
Product (derivative)	2
Product	1

Return to Table of Contents

andexanet alfa

andexanet alfa SNAPSHOT

Drug Name	andexanet alfa
Key Synonyms	andexanet alfa
Originator Company	Portola Pharmaceuticals Inc
Active Companies	Portola Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Bleeding
Target-based Actions	Factor Xa antagonist
Other Actions	Antidote;Coagulation stimulator
Technologies	Biological therapeutic;Parenteral formulation unspecified;Intravenous formulation;Infusion;Protein recombinant
Last Change Date	04-Feb-2014

andexanet alfa DEVELOPMENT PROFILE

SUMMARY

Portola Pharmaceuticals is developing an intravenous formulation of andexanet alfa (PRT-4445, PRT-064445), a recombinant factor Xa derivative as a universal factor Xa inhibitor antidote, for the potential treatment of bleeding in patients taking anticoagulants ,. In December 2012, a phase II trial was initiated ; in June 2013, the positive data from the trial were presented. In November 2013, the company planned to initiate registration-enabling studies in 2014.

andexanet alfa DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Portola Pharmaceuticals Inc	Bleeding	US	Phase 2 Clinical	10-Dec-2012

Return to Table of Contents

andexanet alfa DRUG NAMES

Names	Type
PRT-064445	Research Code
PRT-4445	Research Code
anticoagulant antidote (bleeding), Portola	
andexanet alfa	PINN
factor Xa inhibitor antidote (bleeding), Portola	

andexanet alfa CLINICAL TRIALS

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	1	0	1	0	0	0	2

Return to Table of Contents

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Portola Pharmaceuticals Inc	3	0	2	0	5
Bayer AG	1	0	0	0	1
Johnson & Johnson	1	0	0	0	1
Daiichi Sankyo Co Ltd	0	0	1	0	1
Bristol-Myers Squibb Co	0	0	1	0	1
Pfizer Inc	0	0	1	0	1

Return to Table of Contents

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development Services	3	0	3
Drug - Screening/Evaluation	2	0	2

Return to Table of Contents

PATENTS

Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Portola Pharmaceuticals Inc	5	0	5

Patents by Drug Relationship Type Chart



Return to Table of Contents

Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	2
Product	1
Component of Combination	1
Process	1

Return to Table of Contents

cerdulatinib

cerdulatinib SNAPSHOT

Drug Name	cerdulatinib
Key Synonyms	cerdulatinib
Originator Company	Portola Pharmaceuticals Inc
Active Companies	Aciex Therapeutics Inc;Portola Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Non-Hodgkin lymphoma;Chronic lymphocytic leukemia;Ocular disease;Rheumatoid arthritis
Target-based Actions	Syk tyrosine kinase inhibitor;JAK tyrosine kinase inhibitor
Other Actions	Anti-inflammatory;Apoptosis stimulator;Anticancer protein kinase inhibitor
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	14-Jan-2014

cerdulatinib DEVELOPMENT PROFILE

SUMMARY

Portola Pharmaceuticals is developing cerdulatinib (PRT-2070; PRT-062070), a Syk, JAK multikinase inhibitor, for the potential oral treatment of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and rheumatoid arthritis (RA),. Licensee Aciex Therapeutics is also investigating dual Syk/JAK inhibitors for the potential treatment of topical ophthalmic diseases, including ocular allergy, dry eye and other inflammatory eye conditions. In October 2013, a phase I/II trial was initiated for CLL and NHL. At that time, initial data from the trial were expected in 2014. In June 2012, the drug was listed as being in phase I.

cerdulatinib DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Portola Pharmaceuticals Inc	Chronic lymphocytic leukemia	US	Phase 2 Clinical	09-Oct-2013
Portola Pharmaceuticals Inc	Non-Hodgkin lymphoma	US	Phase 2 Clinical	09-Oct-2013
Portola Pharmaceuticals Inc	Rheumatoid arthritis	US	Phase 1 Clinical	21-Jun-2012
Aciex Therapeutics Inc	Ocular disease	US	Discovery	27-Feb-2013

Return to Table of Contents

cerdulatinib DRUG NAMES

Names	Type
PRT-062070	Research Code
Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals	
cerdulatinib	PINN
PRT-2070	Research Code
dual Syk/JAK inhibitors (ophthalmic disease), Aciex Therapeutics	

cerdulatinib CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Chronic lymphocytic leukemia											
0	0	0	0	0	0	0	2	0	0	0	2
Non-Hodgkin lymphoma											
0	0	0	0	0	0	0	2	0	0	0	2
Follicle center lymphoma											
0	0	0	0	0	0	0	1	0	0	0	1
Hematological neoplasm											
0	0	0	0	0	0	0	1	0	0	0	1
Mantle cell lymphoma											
0	0	0	0	0	0	0	1	0	0	0	1
Diffuse large B-cell lymphoma											
0	0	0	0	0	0	0	1	0	0	0	1

Return to Table of Contents

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	2	0	0	0	2

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

cerdulatinib DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Active Deals
Total: 2

Return to Table of Contents

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Portola Pharmaceuticals Inc	1	0	1	0	2
ORA Inc	1	0	0	0	1
Aciex Therapeutics Inc	0	0	1	0	1

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development Services	1	0	1
Drug - Early Research/Development	1	0	1

Return to Table of Contents

PATENTS

Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Portola Pharmaceuticals Inc	1	0	1

Patents by Drug Relationship Type Chart



Return to Table of Contents

Patents by Drug Relationship Type Table

Drug Relationship	Total
Tentative	1

Return to Table of Contents

PRT-2607

PRT-2607 SNAPSHOT

Drug Name	PRT-2607
Key Synonyms	
Originator Company	Portola Pharmaceuticals Inc
Active Companies	Portola Pharmaceuticals Inc;Biogen Idec Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Chronic lymphocytic leukemia;Allergy;Rheumatoid arthritis;Inflammatory disease;Cancer;Systemic lupus erythematosus;Non-Hodgkin lymphoma
Target-based Actions	Syk tyrosine kinase inhibitor
Other Actions	Coagulation inhibitor;Anticancer protein kinase inhibitor;Anti-inflammatory
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	20-Aug-2013

PRT-2607 DEVELOPMENT PROFILE

SUMMARY

Portola Pharmaceuticals in collaboration with Biogen Idec, is developing PRT-2607 (PRT-062607; P-505-15; BIIB-057; structure shown), the lead from a program of oral Syk inhibitors, for the potential treatment of rheumatoid arthritis (RA), non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and systemic lupus erythematosus (SLE). In June 2012, Biogen Idec reported that the drug was in phase II development for RA, SLE and atopy.

Portola was also investigating the drug for the potential treatment of thrombosis. However, by February 2011, this indication no longer appeared on the company's pipeline.

The company is also investigating an oral Syk inhibitor PRT-060318, for the potential treatment of heparin-induced thrombocytopenia.

PRT-2607 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Biogen Idec Inc	Allergy	US	Phase 2 Clinical	12-Jun-2012
Biogen Idec Inc	Rheumatoid arthritis	US	Phase 2 Clinical	12-Jun-2012
Biogen Idec Inc	Systemic lupus erythematosus	US	Phase 2 Clinical	12-Jun-2012

Return to Table of Contents

Company	Indication	Country	Development Status	Date
Portola Pharmaceuticals Inc	Allergy	US	Phase 2 Clinical	12-Jun-2012
Portola Pharmaceuticals Inc	Rheumatoid arthritis	US	Phase 2 Clinical	12-Jun-2012
Portola Pharmaceuticals Inc	Systemic lupus erythematosus	US	Phase 2 Clinical	12-Jun-2012
Portola Pharmaceuticals Inc	Cancer	UK	Phase 1 Clinical	23-Mar-2010
Portola Pharmaceuticals Inc	Chronic lymphocytic leukemia	US	Phase 1 Clinical	21-Feb-2011
Portola Pharmaceuticals Inc	Inflammatory disease	UK	Phase 1 Clinical	23-Mar-2010
Portola Pharmaceuticals Inc	Non-Hodgkin lymphoma	US	Phase 1 Clinical	21-Feb-2011
Portola Pharmaceuticals Inc	Thrombosis	US	No Development Reported	21-Feb-2011

PRT-2607 CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
	4



Name	Type
2607	Research Code
P-505-15	Research Code
PRT-062607	Research Code

Return to Table of Contents

PRT-2607 DRUG NAMES

Names	Type
PRT-2607	Research Code
2607	Research Code
BIIB-057	Research Code
Syk tyrosine kinase inhibitors (oral, cancers/inflammatory diseases/thrombosis), Portola	
P-505-15	Research Code
P-14276	Research Code
PRT-062607	Research Code

PRT-2607 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Rheumatoid arthritis											
0	0	0	0	0	1	0	0	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	1	0	2	0	0	0	3

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

Return to Table of Contents

PRT-2607 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Portola Pharmaceuticals Inc	1	0	0	0	1
Biogen Idec Inc	0	0	1	0	1

Return to Table of Contents

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

Return to Table of Contents

PATENTS

Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Portola Pharmaceuticals Inc	2	0	2

Patents by Drug Relationship Type Chart



Return to Table of Contents

Patents by Drug Relationship Type Table

Drug Relationship	Total
Component of Combination	2

Return to Table of Contents

PRT-060318

PRT-060318 SNAPSHOT

Drug Name	PRT-060318
Key Synonyms	
Originator Company	Portola Pharmaceuticals Inc
Active Companies	Portola Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	B-cell acute lymphoblastic leukemia;Heparin induced thrombocytopenia
Target-based Actions	Syk tyrosine kinase inhibitor
Other Actions	Coagulation inhibitor;Anticancer protein kinase inhibitor
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	08-Jan-2013

PRT-060318 DEVELOPMENT PROFILE

SUMMARY

Portola Pharmaceuticals is investigating PRT-060318 (PRT-318), an oral Syk inhibitor, for the potential treatment of heparin-induced thrombocytopenia (HIT) and B-cell acute lymphoblastic leukemia , . In December 2008, preclinical studies were ongoing. In August 2011, data were publsihed. in December 2012, preclinical data were presented.

PRT-060318 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Portola Pharmaceuticals Inc	B-cell acute lymphoblastic leukemia	US	Discovery	10-Dec-2012
Portola Pharmaceuticals Inc	Heparin induced thrombocytopenia	US	Discovery	08-Dec-2008

PRT-060318 DRUG NAMES

Names	Type
PRT-318	Research Code
PRT-060318	Research Code
syk inhibitor (oral, heparin-induced thrombocytopenia), Portola	

Return to Table of Contents

Return to Table of Contents

JAK tyrosine kinase inhibitors (oral, inflammatory disease/myelodysplastic syndromes), Portola

JAK tyrosine kinase inhibitors (oral, inflammatory disease/myelodysplastic syndromes), Portola SNAPSHOT

Drug Name	JAK tyrosine kinase inhibitors (oral, inflammatory disease/myelodysplastic syndromes), Portola
Key Synonyms	
Originator Company	Portola Pharmaceuticals Inc
Active Companies	Portola Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Inflammatory disease;Myelodysplastic syndrome
Target-based Actions	Jak1 tyrosine kinase inhibitor;Jak2 tyrosine kinase inhibitor;Jak3 tyrosine kinase inhibitor
Other Actions	Anti-inflammatory;Anticancer
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	17-Jan-2012

JAK tyrosine kinase inhibitors (oral, inflammatory disease/myelodysplastic syndromes), Portola DEVELOPMENT PROFILE

SUMMARY

Portola Pharmaceuticals is investigating a series of oral JAK tyrosine kinase inhibitors specific for JAK2, JAK3 and JAK3/1 for the potential treatment of inflammatory disease and myelodysplastic syndromes,. In September 2009, the program was listed as being in preclinical development. In October 2011, development was ongoing. In January 2012, the company was seeking to outlicense the program.

JAK tyrosine kinase inhibitors (oral, inflammatory disease/myelodysplastic syndromes), Portola DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Portola Pharmaceuticals Inc	Inflammatory disease	US	Discovery	09-Jul-2008
Portola Pharmaceuticals Inc	Myelodysplastic syndrome	US	Discovery	09-Jul-2008

JAK tyrosine kinase inhibitors (oral, inflammatory disease/myelodysplastic syndromes), Portola DRUG NAMES

Names	Type
JAK tyrosine kinase inhibitors (oral, inflammatory disease/myelodysplastic syndromes), Portola	
JAK2, JAK3 and JAK3/1 inhibitors (oral, inflammatory disease/myelodysplastic syndromes), Portola	

Return to Table of Contents

Return to Table of Contents

non-sulfonylurea P2Y12 antagonists (cardiovascular disease), Portola

non-sulfonylurea P2Y12 antagonists (cardiovascular disease), Portola SNAPSHOT

Drug Name	non-sulfonylurea P2Y12 antagonists (cardiovascular disease), Portola
Key Synonyms	
Originator Company	Portola Pharmaceuticals Inc
Active Companies	Portola Pharmaceuticals Inc
Inactive Companies	
Highest Status	Suspended
Active Indications	Cardiovascular disease
Target-based Actions	P2Y12 purinoceptor antagonist
Other Actions	Coagulation inhibitor;Platelet aggregation inhibitor
Technologies	Stereochemistry;Small molecule therapeutic
Last Change Date	25-Sep-2009

non-sulfonylurea P2Y12 antagonists (cardiovascular disease), Portola DEVELOPMENT PROFILE

SUMMARY

Portola was investigating a series of non-sulfonylurea P2Y12 antagonists, including PRT-060096 (structure shown), PRT-060280 and PRT-060288 and the enantiomers PRT-060592 and PRT-060674, as follow-up compounds to elinogrel, for the potential treatment of cardiovascular disease. However, by March 2009, development of the series had been suspended.

non-sulfonylurea P2Y12 antagonists (cardiovascular disease), Portola DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Portola Pharmaceuticals Inc	Cardiovascular disease	US	Suspended	22-Mar-2009

non-sulfonylurea P2Y12 antagonists (cardiovascular disease), Portola CHEMICAL STRUCTURES

Return to Table of Contents

CAS Registry Number:	Confidence Level:
	5



Name	Type
PRT-060096	Research Code

CAS Registry Number:	Confidence Level:
	5



Name	Type
PRT-060288	Research Code

CAS Registry Number:	Confidence Level:
	5



Name	Type
PRT-060392	Research Code

Return to Table of Contents

non-sulfonylurea P2Y12 antagonists (cardiovascular disease), Portola DRUG NAMES

Names	Type
PRT-061110	Research Code
PRT-061171	Research Code
PRT-060280	Research Code
PRT-060674	Research Code
non-sulfonylurea P2Y12 antagonists (cardiovascular disease), Portola	
PRT-060392	Research Code
PRT-061105	Research Code
PRT-060096	Research Code
PRT-060288	Research Code
PRT-061106	Research Code
PRT-060592	Research Code
PRT-060289	Research Code

Return to Table of Contents

elinogrel (oral, cardiovascular events), Portola/Novartis

elinogrel (oral, cardiovascular events), Portola/Novartis SNAPSHOT

Drug Name	elinogrel (oral, cardiovascular events), Portola/Novartis
Key Synonyms	elinogrel potassium;elinogrel
Originator Company	Portola Pharmaceuticals Inc
Active Companies	Portola Pharmaceuticals Inc
Inactive Companies	Novartis AG
Highest Status	Suspended
Active Indications	Coronary artery disease
Target-based Actions	P2Y12 purinoceptor antagonist
Other Actions	Platelet aggregation inhibitor;Coagulation inhibitor
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	16-Aug-2012

elinogrel (oral, cardiovascular events), Portola/Novartis DEVELOPMENT PROFILE

SUMMARY

Portola Pharmaceuticals was developing an oral formulation of elinogrel (PRT-060128; PRT-60128, PRT-128; structure shown), a reversible P2Y12 ADP receptor antagonist that inhibits platelet aggregation, for the potential prevention of myocardial infarction, stroke and death in patients with acute coronary syndrome (ACS), and secondary thrombotic events. In December 2008, Portola initiated a phase II trial in patients undergoing non-urgent percutaneous coronary intervention (PCI). In August 2010, a phase III trial was scheduled to begin in the first quarter of 2011 ; in October 2011, the phase III program was still in planning. In April 2010, filing was expected for 2013. However, in January 2012, Portola reported that it had no plan to invest its resources to advance the drug, and hence would not proceed with its planned phase III trial (ECLIPSE). At that time, Novartis and Portola were under discussions on ways to potentially move the drug forward under a revised agreement that did not require Portola funding.

The company was also developing an intravenous formulation of elinogrel.

The drug was previously being developed in collaboration with Novartis. In February 2009, Novartis acquired rights to the drug. In January 2011, Novartis did not expect a filing before 2015. However, by December 2011, the company had discontinued further development of the drug.

elinogrel (oral, cardiovascular events), Portola/Novartis DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Portola Pharmaceuticals Inc	Coronary artery disease	Canada	Suspended	12-Jan-2012

Return to Table of Contents

Company	Indication	Country	Development Status	Date
Portola Pharmaceuticals Inc	Coronary artery disease	Europe	Suspended	12-Jan-2012
Portola Pharmaceuticals Inc	Coronary artery disease	US	Suspended	12-Jan-2012
Novartis AG	Coronary artery disease	Switzerland	Discontinued	31-Dec-2011

elinogrel (oral, cardiovascular events), Portola/Novartis CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
	2



Name	Type
elinogrel	INN; USAN
PRT-60128	Research Code
PRT-128	Research Code
PRT-060128	Research Code

CAS Registry Number:	Confidence Level:
	2



Name	Type
elinogrel potassium	USAN
PRT-060128 potassium	Research Code

Return to Table of Contents

CAS Registry Number:	Confidence Level:
	4



Name	Type
PRT-060301	Metabolite

elinogrel (oral, cardiovascular events), Portola/Novartis DRUG NAMES

Names	Type
ADP antagonist (oral, acute coronary syndrome), Portola	
PRT-60128 (oral), Portola	Research Code
PRT-060128	Research Code
PRT-060128 potassium	Research Code
direct-acting P2Y12 antagonist (oral), Portola	
PRT-128 (oral), Portola/Novartis	Research Code
elinogrel (oral, cardiovascular events), Portola/Novartis	
PRT-060128 (oral, cardiovascular disease), Portola	
elinogrel potassium	USAN
elinogrel potassium (oral, cardiovascular disease), Portola	
platelet adhesion inhibitor (cardiovascular disorders), Portola Pharmaceuticals	
PRT-060301	Metabolite
elinogrel	INN, USAN
PRT-128	Research Code
PRT-60128	Research Code

Return to Table of Contents

elinogrel (oral, cardiovascular events), Portola/Novartis CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Thrombosis											
0	0	0	0	0	0	0	2	0	1	0	3
Coronary artery disease											
0	0	0	0	0	1	0	2	0	0	0	3
Coronary thrombosis											
0	0	0	0	0	1	0	0	0	0	0	1
Renal disease											
0	0	0	0	0	0	0	1	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	1	0	4	0	1	0	6

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

Return to Table of Contents

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Portola Pharmaceuticals Inc	1	0	0	0	1
Novartis AG	0	0	1	0	1

Return to Table of Contents

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

Return to Table of Contents

PATENTS

Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Portola Pharmaceuticals Inc	9	0	9
Novartis AG	3	0	3
Individual	2	0	2
Takeda Pharmaceutical Co Ltd	1	2	2
Patheon Pharmaceuticals Inc	1	0	1

Return to Table of Contents

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	3
Formulation	3
Product (derivative)	2
Product	1
Process	1
Component of Combination	1

Return to Table of Contents

elinogrel (intravenous, cardiovascular events), Portola/Novartis

elinogrel (intravenous, cardiovascular events), Portola/Novartis SNAPSHOT

Drug Name	elinogrel (intravenous, cardiovascular events), Portola/Novartis
Key Synonyms	elinogrel;elinogrel potassium
Originator Company	Portola Pharmaceuticals Inc
Active Companies	Portola Pharmaceuticals Inc
Inactive Companies	Novartis AG
Highest Status	Suspended
Active Indications	Coronary artery disease
Target-based Actions	P2Y12 purinoceptor antagonist
Other Actions	Coagulation inhibitor;Platelet aggregation inhibitor
Technologies	Intravenous formulation;Small molecule therapeutic
Last Change Date	16-Aug-2012

elinogrel (intravenous, cardiovascular events), Portola/Novartis DEVELOPMENT PROFILE

SUMMARY

Portola Pharmaceuticals was developing elinogrel (PRT-060128; PRT-60128, PRT-128; structure shown), a reversible P2Y12 ADP receptor antagonist that inhibits platelet aggregation, as a potential iv prevention of death, myocardial infarction and stroke in patients with acute coronary syndrome (ACS), and secondary thrombotic events. In November 2007, Portola initiated a phase II trial ; a further phase II trial began in December 2008. In August 2010, a phase III trial was planned to begin in the first quarter of 2011. However, in January 2012, Portola reported that it had no plan to invest its resources to advance the drug, and hence would not proceed with its planned phase III trial (ECLIPSE). At that time, Novartis and Portola were under discussions on ways to potentially move the drug forward under a revised agreement that did not require Portola funding.

An oral formulation of the drug was also being developed.

The drug was previously being developed in collaboration with Novartis. In February 2009, Novartis acquired rights to the drug. In April 2010, filing was expected for 2013 ; however, in January 2011, Novartis did not expect filing to be before 2015. However, by December 2011, the company had discontinued further development of the drug.

elinogrel (intravenous, cardiovascular events), Portola/Novartis DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Portola Pharmaceuticals Inc	Coronary artery disease	Canada	Suspended	12-Jan-2012

Return to Table of Contents

Company	Indication	Country	Development Status	Date
Portola Pharmaceuticals Inc	Coronary artery disease	Europe	Suspended	12-Jan-2012
Portola Pharmaceuticals Inc	Coronary artery disease	US	Suspended	12-Jan-2012
Novartis AG	Coronary artery disease	Switzerland	Discontinued	31-Dec-2011

elinogrel (intravenous, cardiovascular events), Portola/Novartis CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
	2



Name	Type
elinogrel	INN; USAN
PRT-060128	Research Code
PRT-60128	Research Code
PRT-128	Research Code

CAS Registry Number:	Confidence Level:
	2



Name	Type
elinogrel potassium	USAN
PRT-060128 potassium	Research Code

Return to Table of Contents

elinogrel (intravenous, cardiovascular events), Portola/Novartis DRUG NAMES

Names	Type
PRT-060128 (intravenous, cardiovascular disease), Portola	
elinogrel	INN, USAN
elinogrel potassium	USAN
ADP antagonist (intravenous, acute coronary syndrome), Portola	
elinogrel (intravenous, cardiovascular events), Portola/Novartis	
PRT-060128 potassium	Research Code
PRT-60128 (intravenous), Portola	Research Code
direct-acting P2Y12 antagonist (iv), Portola	
PRT-128 (intravenous), Portola/Novartis	Research Code
PRT-060128 (iv, cardiovascular disease), Portola	
PRT-128	Research Code
PRT-60128	Research Code
PRT-060128	Research Code
elinogrel potassium (iv, cardiovascular disease), Portola	

elinogrel (intravenous, cardiovascular events), Portola/Novartis CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Myocardial infarction											
0	0	0	0	0	1	0	0	0	0	0	1
Thrombosis											
0	0	0	0	0	0	0	1	0	0	0	1
Coronary thrombosis											
0	0	0	0	0	1	0	0	0	0	0	1

Return to Table of Contents

Coronary artery disease											
0	0	0	0	0	1	0	0	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	2	0	1	0	0	0	3

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

elinogrel (intravenous, cardiovascular events), Portola/Novartis DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Return to Table of Contents

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Novartis AG	0	0	1	0	1
Portola Pharmaceuticals Inc	1	0	0	0	1

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

Return to Table of Contents

PATENTS

Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Portola Pharmaceuticals Inc	7	0	7
Novartis AG	3	0	3
Takeda Pharmaceutical Co Ltd	1	2	2
Individual	2	0	2

Return to Table of Contents

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	2
Product (derivative)	2
Formulation	2
Process	1
Product	1
Component of Combination	1

Return to Table of Contents

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:
http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

Return to Table of Contents